Clindamycin Injection USP — Class II drug recall D-0941-2017
Terminated recall by Alvogen, Inc, reported 2017-07-12, distributed nationwide. Lack of Assurance of Sterility
| Recall number | D-0941-2017 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Alvogen, Inc, Pine Brook, NJ, United States |
| Recall initiated | 2017-06-16 |
| Classified | 2017-07-03 |
| Reported by FDA | 2017-07-12 |
| Terminated | 2019-10-30 |
| Distributed | Nationwide (US) |
| Quantity | 71,825 |
| Reason classes | sterility |
| NDC | 47781-0464-69 |
| Lot numbers | 68-105-EV, 68-106-EV, 73-157-EV |
| Expiration dates | 2018-07-31, 2018-12-31 |
Product
Clindamycin Injection USP; 900 mg/6 mL (150 mg/mL). 6 mL Single-dose ADD-VANTAGE Vial, Rx Only, Manufactured for Alvogen, Inc., Pine Brook, NJ 07058, NDC 47781-464-69
Reason for recall
Lack of Assurance of Sterility
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0941-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.